Diligence memo · auto-generated · as of July 2, 2026
Episteme Prognostics, Inc.
Episteme Prognostics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Episteme Prognostics, Inc. operates in Biotechnology, based in Brooklyn.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Episteme Prognostics, Inc. has raised $4.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.1M on 2023-03-31.
Most recent recorded round closed around 2025-02-21.
Valuation (modeled)modeled
Provath models Episteme Prognostics, Inc. at approximately $2.1M (range $600K–$3.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.14× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 7.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 42% of Biotechnology peers (4293 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.